Labcorp announced on April 23, 2025, the expansion of its precision oncology portfolio with two new solutions: Labcorp Plasma Detect and PGDx elio plasma focus Dx. Labcorp Plasma Detect is now available for clinical use to assess the risk of disease recurrence in stage III colon cancer patients, a group with a nearly 30% recurrence rate within five years.
Labcorp Plasma Detect is a blood-based test utilizing whole-genome sequencing (WGS) to detect circulating tumor DNA (ctDNA), indicating the presence of molecular residual disease (MRD). This test helps identify patients at higher risk of recurrence who may benefit from additional treatment, detecting risks that conventional methods might miss.
Additionally, Labcorp announced the availability of PGDx elio plasma focus Dx, the first and only kitted, pan-solid tumor liquid biopsy test authorized by the U.S. Food and Drug Administration (FDA). This assay provides oncologists with a validated tool to assess various solid tumors for targeted treatment selection from a simple blood draw, advancing care across the oncology spectrum.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.